Santhera Pharmaceuticals has shared an update with the Duchenne community regarding the Phase 2b trial for vamorolone, which the company expects to have data from in the second quarter of 2021.

Read the full press release here.

Are you participating in one of the vamorolone clinical trials?

Contact Suzanne Gaglianone at Suzanne.gaglianone@reveragen.com to opt-in to receive your study data. Suzanne will walk you through the process and timelines for receiving your individual study data.